Interleukin 6 drives durable T cell-mediated immunity to pancreatic cancer.

ABSTRACT:

Background & aims

Tumor immune resistance is recognized as a contributor to low survivorship in pancreatic ductal adenocarcinoma (PDAC). The inflammatory cytokine interleukin-6 (IL-6) promotes polarization of CD4 T cell populations away from immune tolerance, induces differentiation of cytotoxic CD8 T cells, and drives expansion and anti-tumor activity in chimeric antigen receptor (CAR) T cell therapies. This work aims to test whether IL-6 could stimulate an anti-tumor response in PDAC.

Methods

We overexpressed IL-6 in multiple Kras ^G12D/+ , Tp53 ^R172H/+, Pdx1-Cre (KPC) cell lines, which were orthotopically implanted in mice (OT-PDAC ^IL6 ). We followed mouse survival and measured tumor growth, tumor histology, and plasma IL-6 at 5 and 10 days

SUBMITTER: Arneson-Wissink PC 

PROVIDER: S-EPMC11463358 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature